Insight
Redefining quality of life: The role of non-invasive treatments in women’s health
By Gloria Kolb, Co-founder & CEO – Elitone
In women’s healthcare, the options for treating various conditions have traditionally leaned heavily toward surgical or pharmaceutical interventions.
While these treatments are effective in many cases, they often come with risks, downtime, and long-term side effects.
From surgeries that require lengthy recovery periods to medications with potential side effects that can disrupt daily life, these options can significantly impact a woman’s quality of life.
However, as healthcare evolves, so does the demand for more non-invasive solutions. Today, women seek alternatives that provide relief without compromising their lifestyles or health.
Non-invasive treatments offer a refreshing departure from conventional approaches that often prioritise more intrusive methods because they are designed to be less disruptive, allowing women to continue with their lives without significant interruptions.
Wearable treatments, lifestyle modifications, and other non-invasive options improve the overall quality of life in women’s health by prioritising their balance, well-being, and control.
The push toward surgical and pharmaceutical solutions
The traditional medical and pharmaceutical communities often lean toward surgical or pharmaceutical interventions for various reasons, not the least of which is profitability.
Surgical procedures and long-term pharmaceutical treatments are not only more lucrative for healthcare providers but also offer a clear-cut, often immediate, solution to certain health conditions.
For example, surgeries for conditions like incontinence, pelvic organ prolapse, or other women’s health issues are commonly marketed as a definitive “fix.”
Medications, meanwhile, are often prescribed to manage symptoms over the long term.
While this approach can create continued profits for pharmaceutical companies, clinicians do not prescribe medications with this in mind.
Rather, medications are often seen as a quick and straightforward solution: a prescription that gets a patient on their way with minimal effort required in the short term.
However, these solutions can come at a significant cost to the women undergoing them.
Surgical procedures can involve weeks of recovery, potential complications, and even repeat operations. They can be costly, and copays and deductibles are substantial.
Additionally, while pharmaceutical interventions can be less invasive than surgery, they often come with a range of side effects specific to the condition being treated.
For instance, medications for endometriosis or hormone replacement therapy can lead to weight gain, fatigue, or hormone imbalances, which can disrupt daily life and add stress for many women.
These trade-offs are often a source of frustration, as managing the side effects can feel like swapping one problem for another. Incorporating broader examples of women’s health issues, such as endometriosis, polycystic ovary syndrome (PCOS), or menopause, makes the conversation around treatment options more relatable and comprehensive.
What non-invasive treatments offer
Non-invasive treatments, by contrast, redefine what it means to manage health conditions.
While clinicians may define “non-invasive” as strictly non-surgical, the broader perspective includes treatments that avoid physical intrusion, require fewer clinician visits, and don’t demand significant time off work or logistical challenges like arranging transportation.
These hurdles often discourage women from completing or even starting the care they need.
Non-invasive options remove these barriers, making it more likely that women will adhere to and benefit from treatment.
In medical terms, this approach is often referred to as “conservative” treatment. The idea is to try solutions that don’t permanently alter the body or limit future options.
For example, once a surgical implant is placed, other procedures become more complicated or unavailable.
Conservative treatments, by contrast, allow women to explore other options later if needed.
Take, for example, wearable treatments for incontinence. These devices offer a discreet, non-invasive way to treat symptoms by strengthening the pelvic floor muscles over time.
Wearable treatments don’t require surgery or even any downtime. Women can go about with their tasks while getting treatment.
Furthermore, women don’t have to wear the device all day — it only takes up to 20 minutes — and many of these non-invasive options are designed to address multiple conditions beyond incontinence, including pelvic pain, hormonal imbalances, or menstrual irregularities.
By working with the body’s natural rhythms, they offer a gentler alternative to conventional treatments.
This alignment with the body allows women to feel in control of their health, pursuing treatment that supports their needs without dominating their lives.
Redefining quality of life for women
Quality of life is a concept that extends beyond simply managing symptoms.
It encompasses a woman’s overall well-being and ability to engage fully in her relationships, work, and personal interests without being hindered by her health.
Non-invasive treatments offer solutions that respect this broader definition of wellness.
For instance, non-invasive treatments such as pelvic floor therapy or low-impact physical therapies can help women regain control of their bodies without the need for surgery.
These treatments encourage gradual, natural improvement over time, allowing women to recover strength and function at their own pace.
There’s no need for a significant disruption to daily life. which is particularly important for women who balance multiple roles — whether in the workforce, at home, or both.
Similarly, lifestyle modifications such as dietary changes, stress management techniques, or even behavioral therapies can be instrumental in managing women’s health conditions without the need for aggressive treatments.
These approaches support physical health and mental and emotional well-being, reinforcing the idea that quality of life is multidimensional.
When women have access to non-invasive treatments, they are empowered to make choices about their healthcare that prioritise their personal and professional lives.
This is crucial in an era when women are managing more than ever — family, career, personal development, and health.
Non-invasive treatments offer a way to balance these aspects without sacrificing well-being.
The future of non-invasive treatments in women’s health
As more women demand non-invasive options, the healthcare landscape is gradually shifting.
Wearable devices, digital health solutions, and other innovations make it easier for women to take control of their health without feeling like their condition controls them.
In particular, the rise of Femtech — technology designed to address women’s health issues — has brought an array of non-invasive options to the forefront.
From wearable treatments for pelvic floor strengthening to apps that track and manage menstrual cycles, to cooling mechanisms for hot flashes, and digital solutions for hormone balance, these innovations prioritise convenience and accessibility.
The future of women’s health lies in individualised, non-intrusive care.
These advancements offer women the opportunity to prioritise their health without excessive sacrifices to their quality of life.
Non-invasive treatments provide effective solutions without requiring significant time, recovery, or compromise, empowering women to manage their health in a way that is both practical and respectful of their responsibilities.
The future of women’s health lies in technologies that allow for individualised, nonintrusive care.
Rather than forcing women to choose between their health and their quality of life, non-invasive treatments allow women to have both by providing effective solutions that don’t demand significant time, recovery, or compromise.
This shift is not just about better healthcare; it’s about a better approach to healthcare that respects women’s needs and preferences and redefines what it means to live well.
Non-invasive treatments recognise that quality of life is more than symptom management and entails supporting a woman’s ability to thrive in all areas of her life without being held back by the limitations of more traditional medical treatments.
Gloria Kolb is the CEO and co-founder of Elitone, the first non-invasive, FDA-cleared, wearable treatment for women with urinary incontinence. Elitone’s accolades include winning Best New Product by My Face My Body, Sling Shot 2020, CES Innovation Award, and many startup competitions. As an inventor with 30+ patents, Gloria has been featured in Forbes as a Top Scientist Driving Innovation in Women’s Health. Her creative designs and problem-solving abilities have earned her recognition, such as Boston’s “40 Under 40” and MIT Review’s “World’s Top Innovators under 35.” She has engineering degrees from MIT and Stanford, as well as an MBA in entrepreneurship from Babson College.
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
News
WHO hosts parliamentary dialogue on women’s health
The World Health Organization (WHO) welcomed a delegation of parliamentarians to its Geneva headquarters for a high-level dialogue on women’s health and sexual and reproductive health and rights.
The meeting on 20 January 2026 focused on women’s health, sexual and reproductive health and rights, noncommunicable diseases (long-term conditions such as cancer and diabetes) and global health cooperation.
The exchange was convened by the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, bringing together parliamentarians from Albania, Germany, Georgia, Mexico, Slovakia, South Africa, Sri Lanka, Sweden and Zimbabwe.
A central theme was the need to move beyond fragmented approaches to women’s health.
Dr Alia El-Yassir, WHO director for gender, equity and diversity, highlighted that outcomes are shaped by gender inequalities, social norms and structural barriers across the life course, requiring coordinated action across health systems.
Thirty years after the Beijing Declaration and Platform for Action, a landmark framework adopted in 1995 to advance gender equality and women’s rights, Dr Anna Coates, WHO gender equality technical lead, noted that progress on women’s health remains uneven.
She called for health systems that are more gender-responsive and able to address women’s health holistically across the life course.
Parliamentarians stressed that health is inseparable from wider social and economic policies, and called for stronger links between evidence, legislation and measurable impact at country level.
The meeting also focused on sexual and reproductive health and rights, where parliamentarians expressed interest in engaging on issues that directly affect their constituents.
Dr Pascale Allotey, director of WHO’s Department of Sexual, Reproductive, Maternal, Child, Adolescent Health and Ageing, outlined WHO’s life-course approach to sexual and reproductive health and rights.
She highlighted how needs evolve from birth to older age and how these are shaped by social determinants, humanitarian crises and demographic trends.
Dr Allotey underscored the role of parliamentarians in advancing sexual and reproductive health and rights and the importance of continued engagement with WHO to support evidence-based policy-making.
The agenda highlighted cancer as a growing priority for women’s health and for health system sustainability. Dr Prebo Barango, lead for the Cervical Cancer Elimination Initiative, Dr Meghan Doherty, consultant for palliative care, and Santiago Milan, lead for the WHO Global Platform for Access to Childhood Cancer Medicine, presented WHO’s integrated approach to cancer control.
Palliative care is treatment and support that aims to improve quality of life for people with serious illness by managing pain and other symptoms.
The discussion underlined the need for sustained political commitment and domestic investment to address noncommunicable diseases.
Parliamentarians shared national experiences showing the social and economic impacts of cancer on families and caregivers, reinforcing the importance of improving health literacy, reducing stigma and delivering people-centred care.
The meeting also addressed the state of global multilateralism.
Dr Jeremy Farrar, assistant director-general for health promotion, disease prevention and care, outlined how WHO has restructured to enhance efficiency, impact and capacity to support countries.
He reaffirmed WHO’s commitment to more systematic engagement with parliaments, recognising their role in shaping health policy, legislation and budgets.
The exchange concluded with a call for continued collaboration, including through partnerships with the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, ahead of the UNITE Global Summit 2026 on 6–7 March in Manila, the Philippines.
Insight
FDA approves Agilent test for ovarian cancer
Agilent has FDA approval for a test to identify ovarian cancer patients who may be eligible for immunotherapy.
Agilent’s PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic to help identify patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours express PD-L1 and who may be eligible for treatment with KEYTRUDA, Merck’s anti-PD-1 therapy.
A companion diagnostic is a test used alongside a specific treatment to show whether a patient is suitable for that therapy. PD-L1 is a protein on some cancer cells that helps tumours evade the immune system.
These cancers affect the reproductive system and the lining of the abdominal cavity.
The test enables pathologists to assess PD-L1 expression at diagnosis to support treatment decisions in a disease where options remain limited for many.
This is the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA.
Nina Green, vice president and general manager of Agilent’s clinical diagnostics division, said: “Delivering effective precision oncology requires close collaboration between diagnostics and therapeutics, and this FDA approval reflects Agilent’s long-standing industry partnership in companion diagnostics.
“We are proud to enable pathologists to identify patients with EOC who may benefit from immunotherapy.
“As the first immuno-oncology approval for this disease, this milestone underscores our commitment to advancing precision medicine and expanding access to innovative cancer treatments worldwide.”
PD-L1 expression with this test was evaluated in the KEYNOTE-B96 clinical trial supporting its use to identify patients who may benefit from KEYTRUDA.
In the US, ovarian cancer caused approximately 12,730 deaths in 2025 and the five-year survival rate was 51.6 per cent between 2015 and 2021.
In addition to these cancer types, the test is indicated in the US to help identify patients with non-small cell lung cancer, oesophageal squamous cell carcinoma, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer and gastric or gastro-oesophageal junction adenocarcinoma who may benefit from treatment with KEYTRUDA.
The test was developed by Agilent with Merck as a companion diagnostic for KEYTRUDA.
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health





